Associated Papers
Comprehensive genetic profiling using tissue and blood in locally advanced tumors.
Fujiyoshi K et al.
Oncology Reports, 2025
Clinical Validation of Local Versus Commercial Genomic Testing in Cancer: A Comparison of Tissue and Plasma Concordance.
Faulkner LG et al.
Cancer Investigation, 2025
Evolutionary history of MEK1 illuminates the nature of deleterious mutations.
Andrianova EP et al.
Proceedings of the National Academy of Sciences of the United States of America, 2023
37579140 (PubMed )
Supplement: pnas.2304184120.sapp.pdf
Dissecting mechanisms of resistance to targeted drug combination therapy in human colorectal cancer.
Clarke PA et al.
Oncogene, 2019
Integrative omics analyses broaden treatment targets in human cancer.
Sengupta S et al.
Genome Medicine, 2018
30053901 (PubMed )
Supplement: 13073_2018_564_MOESM2_ESM.xlsx › 3
Discovery of a novel ERK inhibitor with activity in models of acquired resistance to BRAF and MEK inhibitors.
Morris EJ et al.
Cancer Discovery, 2013
MEK1 mutations confer resistance to MEK and B-RAF inhibition.
Emery CM et al.
Proceedings of the National Academy of Sciences of the United States of America, 2009
Genome Analysis of Osteosarcoma Progression Samples Identifies FGFR1 Overexpression as a Potential Treatment Target and CHM as a Candidate Tumor Suppressor Gene.
Barøy T et al.
Plos One, 0
27685995 (PubMed )
Supplement: pone.0163859.s005.xlsx › OS106
Select a paper to view details